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ADVANCING FDA'S REGULATORY SCIENCE
THROUGH WEIGHT OF EVIDENCE
EVALUATIONS
Joseph W. Cormier
I.

INTRODUCTION

The United States Food and Drug Administration ("FDA" or "the
Agency") regulates roughly one quarter of the country's gross domestic
expenditure.I The breadth of products under its regulatory oversight include
not only most foods, 2 human and veterinary drugs, biologics, medical
devices, dietary supplements, and cosmetics, but also radiation emitting
products, animal feed, and tobacco products.3 Although FDA has long been
recognized as the "gold standard" of science-based regulation of food and
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E.g., U.S. FOOD & DRUG ADMIN., ADVANCING REGULATORY SCIENCE
FDA 2 (2011), http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/
RegulatoryScience/UCM268225.pdf.
1.

AT

2. The U.S. Department of Agriculture, rather than FDA, exercises jurisdiction over
certain meat and poultry products via the Federal Meat Inspection Act, ch. 2907, 34 Stat.
1260 (1907) (codified as amended in scattered sections of 21 U.S.C.), the Poultry
Products Inspection Act, 21 U.S.C. §§ 451-472 (2006), and the Egg Products Inspection
Act, 21 U.S.C. §§ 1031-1056 (2006).
3. See The Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (1938)
[hereinafter FDCA] (codified as amended in scattered sections of 21 U.S.C.).

I

2

The Journalof ContemporaryHealth Law andPolicy Vol. XXVIII:1

medical product safety, as the Agency begins its second century, it is
striving to be more "science-led."4
Indeed, FDA recently stated in an August 2011 report on regulatory
science that:
FDA plays a critical role in protecting and promoting the nation's
health and regulates industries that are among the most successful
and innovative in the world. Critical responsibilities across the
products FDA regulates require application of the best available
science to keep pace with these advances and make decisions and
take actions that both support innovation and protect and promote
the public health.
Advancing this effort-fostering an agency whose regulatory approach is
driven by science, not just founded on general scientific principles-will
require FDA to take a fresh look at regulations and policies that are, in some
cases, decades old.6 While some of these regulations and policies may have
been sufficient at one time, the authors of some of these older regulations
and policies could not have envisioned the types of products or indications
that come before the Agency today.7 In other cases, bright-line rules that
have been applied over time and have become entrenched fail to adequately
address the more nuanced scientific realities of specific applications. In
each case, FDA has in good faith established a regulatory paradigm founded
on sound science. However, when application-specific scientific data
suggest that FDA regulate in a more individualized manner, a science-led
agency should be free to do so.
One example of this issue is in how FDA determines that a new drug or
biologic is effective in meeting its claims and intended use. The Federal

4. Science and Mission at Risk: FDA's Assessment: Hearing Before the H.
Subcomm. on Oversight and Investigations of the H. Comm. on Energy and Commerce,
110th Cong. 156 (2008) (emphasis added) (statement of Andrew C. von Eschenbach,
Commissioner of Food and Drugs), available at http://www.fda.gov/NewsEvents/
Testimony/ucml 15250.htm.
5. U.S.

FOOD

& DRUG ADMIN., supra note 1, at 35.

6. See, e.g., 21 C.F.R. pt. 211 (201) (good manufacturing practices for drug
products). Although Part 211 was first finalized in 1978, 43 Fed. Reg. 45,077, only
minor changes have been made since the mid-1980s. Id.
7. For example, the use of modem biotechnology to genetically engineer animals to
produce human biologics.
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Food, Drug, and Cosmetic Act ("FDCA") requires that sponsors provide
"substantial evidence" demonstrating that their products are effective under
the prescribed conditions for its intended use.8 This article will first review
the statutory requirement and FDA's historical interpretation of "substantial
evidence." Second, the article will argue that a rigid application of FDA's
interpreted standard can lead to scientifically inappropriate results. Third,
the article will: (1) discuss an alternative approach that utilizes a weight of
evidence evaluation when determining the sufficiency of scientific data and
information, and (2) examine two general examples of how such an
approach would be beneficial to FDA, drug and biologic sponsors, and the
general public. Finally, the article will consider some of the policy
considerations that must be taken into account prior to implementing a
weight of evidence approach to data review.
II. THE "SUBSTANTIAL EVIDENCE" REQUIREMENT FOR
CLINICAL EFFECTIVENESS

Manufacturers of drugs and biologics are required to obtain a positive
affirmation of both safety and effectiveness of their products from FDA in
the form of a product approval prior to initial marketing. 9 In reviewing such
applications, FDA ultimately decides if a product's benefits outweigh its
risks.10

A.

Drugs

It has been observed that "[t]he history of clinical trials closely follows the
history of drug regulation."'1 The first federal regulation of drug products,
the Pure Food and Drug Act of 1906, prohibited the sale of misbranded or

8. FDCA § 505(d), 21 U.S.C. § 355(d).
9. FDCA § 505(a), 21 U.S.C. § 355(a) (prohibiting the introduction into interstate
commerce of any drug that has not been approved); Public Health Service Act § 351, 42
U.S.C. § 262(a) (2006) (prohibiting the introduction into interstate commerce of any
biologic that has not been approved).
10.

FDCA § 505(a), 21 U.S.C. § 355(a); Public Health Service Act § 351, 42 U.S.C.

§ 262(a).
11. John H. Powers, Increasing the Efficiency of Clinical Trials of Antimicrobials:
The Scientific Basis of Substantial Evidence of Effectiveness of Drugs, 45 CLINICAL
INFECTIOUs DISEASE 153, 153 (2007).
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adulterated pharmaceuticals. 1 2 In 1938, after more than one hundred Teople
died from using an unsafe drug product, Congress passed the FDCA.I With
the 1938 FDCA, FDA only assessed product safety. This changed in 1962
when concerns about misleading and unsubstantiated product-claims led
Congress to amend the FDCA to include an efficacy requirement.14 Drug
efficacy is evidence of a causal relationship between the product and a
clinical benefit. Researchers and pharmacologists had testified before the
Senate about the importance of quality clinical trials in pharmaceutical
market control.1 The 1962 Kefauver-Harris Amendments to the FDCA
incorporated these concerns into the statutory requirements for FDA market
approval. 16
Under the amended FDCA, sponsors must provide "substantial evidence"
demonstrating that their products are effective under the prescribed
conditions for their intended use.' 7 The FDCA defines "substantial
evidence" as:
evidence

consisting

of

adequate

and

well-controlled

investigations, including clinical investigations, by experts
qualified by scientific training and experience to evaluate the
effectiveness of the drug involved, on the basis of which it could
fairly and responsibly be concluded by such experts that the drug

12. Pure Food and Drug Act of 1906, ch. 3915, 34 Stat. 768 (1906) (repealed 1938
and replaced with the FDCA).
13. See Carol Ballentine, Taste of Raspberries, Taste of Death: The 1937 Elixir
Sulfanilamide Incident, FDA CONSUMER MAGAZINE (Jun. 1981), http://www.fda.gov/
AboutFDA/WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/default.htm.
14. See Milind Kale et al., Monitoring the Regulatory Process of PrescriptionDrug
Advertising, 5 J. PHARMACY & L. 229, 231 (1995) (discussing the motivations behind the
Kefauver-Harris Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780).
15. Jennifer Kulynych, Will FDA Relinquish the "Gold Standard" for New Drug
Approval? Redefining "SubstantialEvidence" in the FDA Modernization Act of 1997,
54 FOOD& DRUG L.J. 127, 134 (1999).
16. See id. at 134 n.48 (discussing expert testimony on effectiveness requirements);
FDA History-PartIII: Drugs and Foods Under the 1938 Act and Its Amendments, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/
ucm055ll8.htm (last updated June 18, 2009).

17.

FDCA § 505(d), 21 U.S.C. § 355(d) (2006).
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will have the effect it purports or is represented to have under the
conditions of the use prescribed, recommended, or suggested in
the labeling or proposed labeling thereof.18
Initially, FDA interpreted "investigations" to mean at least two human
studies were required. 9 Over time, however, FDA permitted the use of a
single study on a case-by-case basis. The Food and Drug Administration
and Modernization Act of 1997 ("FDAMA") codified this practice,
amending the FDCA to explicitly allow for the use of one clinical study to
support substantial evidence under certain limited circumstances.20 FDAMA
specifically provides that FDA may consider "data from one adequate wellcontrolled clinical investigation and confirmatory evidence" to constitute
"substantial evidence" if FDA determines, "based on relevant science," that
the data establishes effectiveness.21
B.

Biologics

The Public Health Service Act ("PHSA") governs the FDA regulatory
approval for biologic products.22 Under PHSA, FDA may approve biologics
once they have been demonstrated to be "safe, pure, and potent."23 In
FDAMA, Congress instructed FDA to minimize the differences in the
24
review and approval of biologics under the PHSA and drugs under FDCA.
Accordingly, FDA has historically interpreted "potency" to mean
effectiveness and incorporates the new drug application standard for

18.

Id. (emphasis added).

19. E.g., Warner-Lambert Co. v. Heckler, 787 F.2d 147, 151 (3rd Cir. 1986). The
term "clinical" in the definition is routinely interpreted to mean "human." See, e.g.,
Russell Katz, FDA: Evidentiary Standards for Drug Development and Approval, I
NEURORX 307, 308 (2004).
20. See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105115, § 115(a), III Stat. 2296, 2313 (1997) [hereinafter FDAMA] (codified in scattered
sections of 21 U.S.C.).
21.

Id § 115(a).

22.

Public Health Service Act § 351(a)(2)(B), 42 U.S.C. § 262(a)(2)(B) (2006).

23.

Id.

24.

FDAMA § 123(t).
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adequate and well-controlled studies to demonstrate effectiveness.25
Therefore, the standards for substantial evidence are essentially identical for
drugs and biologics. 26
C.

HistoricalInterpretation

Since the 1962 amendments to the FDCA, FDA, the pharmaceutical
industry, and the scientific communit at large have debated what constitutes
sufficient evidence of effectiveness. Congress tasked FDA with specifying
the legal and scientific evidentiar requirements by leaving the phrase
FDA has therefore
"adequate and well controlled" 2 undefined.29
promulgated regulations that detail "characteristics . .. recognized by the
scientific community as the essentials of an adequate and well-controlled
clinical investigation." 30 These characteristics specify the criteria for an
"adequate and well-controlled" study: (1) a pre-determined study objective
and method for the analysis of results; (2) a design that allows one to validly
and quantitatively compare the test drug to a control (usually either another
drug or placebo); (3) a method for selecting appropriate subjects; (4) a
method for assigning treatments; (5) methods for minimizing bias from
subjects, observers, and data analysts; (6) methods for assessing subjects'

25. See 21 C.F.R. § 601.25(d)(2) (2011) (incorporating 21 C.F.R. § 314.126 (2011)
(adequate and well-controlled studies for new drug applications) into standards of
evaluating effectiveness for biologics); cf Kulynych, supra note 15, at 137 (citing 21
C.F.R. § 600.3(s) (2011)).
26. Throughout the remainder of the article, unless otherwise noted, the terms "drug"
and "biologic" will be used interchangeably.
27.

U.S. FOOD & DRUG ADMIN., DEP'T OF HEALTH AND HUMAN SERVS., GUIDANCE

FOR INDUSTRY: PROVIDING CLINICAL EVIDENCE OF EFFECTIVENESS FOR HUMAN DRUG AND

BIOLOGICAL PRODUCTS 1 (1998) [hereinafter GUIDANCE ON EVIDENCE],

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guid
ances/UCM072008.pdf.
28.

See FDCA § 505(d), 21 U.S.C. § 355(d) (2006).

29. See FDCA § 701(a), 21 U.S.C. § 371(a) (2006) (granting FDA authority to
promulgate regulations for the efficient enforcement of the FDCA).
30.

21 C.F.R. § 314.126(a).

FDA Weight ofEvidence Evaluations

2011

7

responses; and (7) a description and analysis of results and methods of
evaluation, "including any appropriate statistical methods."3 '
When finalizing this interpretation, FDA stated that the regulation has two
objectives: (1) to minimize bias in clinical studies, and (2) to assure that the
study methods are sufficiently detailed so that FDA can fully assess and
interpret the study data.3 2 Therefore, the goal of adequate and wellcontrolled studies is to produce valid and reliable data and reduce the
likelihood that an observed benefit is something other than a drug effect.33
When assessing the core questions of safety and effectiveness, FDA takes an
empirical approach.34 Regulations "require a quantitative comparison of the
effects of the drug to . .. a control group," 35 but do not require any particular
method of statistical analysis when considering the results.3 6
III.

CLINICAL EVALUATIONS AND STATISTICAL ANALYSIS

FDA's general practice is that applications must include two trials with
However, after FDAMA, FDA published a guidance
significant results.
document detailing the regulatory and scientific considerations for
approving a marketing application based on a single "adequate and wellcontrolled" study. A single study may be sufficient when related data can
substantiate the study-such as new dose regimes for approved productsand when a single multicenter trial provides evidence of effectiveness,
supported by confirmatory research.38
31.

Id. § 314.126(b)(l)-(7).

32.

New Drug and Antibiotic Regulations, 50 Fed. Reg. 7452, 7487 (Feb. 22, 1985).

33. See, e.g., Katz, supra note 19, at 309-10 ("The Agency routinely seeks to
minimize the likelihood that any beneficial effect seen in a drug trial is the result of
[fraud, bias, or chance].").
34.

Id. at 316.

35.

Id. at 311.

36.

Id.

37.

Kulynych, supra note 15, at 149; cf FDCA § 505(d), 21 U.S.C. § 355(d) (2006)

(using the plural "adequate and well-controlled investigations" to describe "substantial
evidence").
38.

GUIDANCE ON EVIDENCE, supra note 27, at 3-4.
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Generally, reliance on a single study is based on an "extreme P-value." 39
FDA has delineated other exceptions to its statistical paradigm, including
regulations on the use of surrogate endpoints.4 0 Restricting the application
of these modified evidentiary requirements to serious illnesses, however,
"reflect[s] the Agency's acknowledgement that these approvals introduce a
level of uncertainty into the approval process that is ordinarily not present
(namely, the uncertainty that the effect of the drug on the surrogate will
predict the desired clinical benefit)."41 As opposed to standard outcome
measures like increased survival, surrogate endpoints are only presumed to
predict desired clinical effects. For example, tumor shrinkage might be
reasonably likely to predict that a product effectively extends cancer
patients' survival. FDA's regulations permit the Agency to approve
products for serious or life-threatening diseases based on clinical trials that
establish that "the drug product has an effect on a surrogate endpoint that is
reasonably likely, based on epiderniologic, therapeutic, pathophysiologic, or
other evidence, to predict clinical benefit."4 2
FDA has stated that "[a]lthough there is no statutory requirement for
significance testing of any particular value, there are well-established
conventions for assessing statistical significance to support the statutorily
required conclusion that the well-controlled studies have demonstrated that a
drug will have the effect it is represented to have."43

39. E.g., Robert Temple, How FDA Currently Makes Decisions on Clinical Studies,
2 CLINICAL TRIALs 276, 277 (2005). The statistical probability that an observed
difference between treatment groups results from chance is represented by the p value.
40. See 21 C.F.R. § 314 Subpart H-Accelerated Approval of New Drugs for Serious
or Life-Threatening Illnesses (2011); see also 21 C.F.R. § 601 Subpart E-Accelerated
Approval of Biological Products (2011).
41.

Katz, supra note 19, at 309.

42.

21 C.F.R. § 314.510.

43. New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated
Approval, 57 Fed. Reg. 58,942, 59,948 (Dec. 11, 1992) (responding to a comment to a
new rule for accelerated approvals of certain drugs and biologics).

2011
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Typically, FDA requires a statistically significant difference in some
measure of clinical signs or symptoms between the treatment and control
groups.44 Significance in this context is how likely it is that a difference as
large as the one observed occurred purely by chance. Results are generally
considered "significant" when the probability of making a false-positive
claim about the beneficial effect of a treatment is less than five percent.45 A
p value of less than 0.05 indicates a less than five percent probability that an
observed drug-benefit occurred by chance.4 6
FDA generally considers a clinical trial to be a success if the p value is
less than or equal to 0.05 when comparing the treatment group to the control
group.47 For example, Dr. Robert Temple, Director of FDA's Office of
Drug Evaluation I, remarked to an FDA advisory panel that "substantial
evidence" of a "clinically meaningful effect" generally "means at least one
study showing a very large effect, or two studies for which the P value is
less than 0.05."4 Although FDA's interpretation of the characteristics of an
adequate and well-controlled study were not intended to be viewed as a

44. See, e.g., Lawrence Gould, Substantial Evidence of Effect, 12 J.
BIOPHARMACEUTICAL STAT. 53, 54 (2007) (describing the traditional application of
"substantial evidence" as two trials demonstrating that the product has a statistically
significant effect).
45. See Henry 1. Miller & David R. Henderson, The FDA 's Risky Risk-Aversion, 145
POL'Y REV. 14, 15-17 (2007) ("Although arbitrary, the bar is typically set at 5 percent ...
as 'proof for most phenomena in the realms of medicine and science.").
46. Jonathan Denne & Gregory Enas, "Substantial Evidence" from a Replicated
Secondary Analysis, Followed by a Single Prospective Confirmatory Study, 42 DRUG
INFO. J. 131, 133 (2008) (discussing the usual statistical standards for making a positive
claim for efficacy).
47. E.g., Katz, supra note 19, at 310; see also Miller & Henderson, supra note 45, at
15-17 (discussing multiple examples of when FDA delayed or denied approval for drugs
that despite other evidence, were not shown to be statistically significant at primary
endpoints, and discussing an example of when FDA required additional studies to
demonstrate effectiveness when initial studies fell short of the p < 0.05 threshold).
48. Miriam E. Tucker, FDA Panel Reviews Nitroglycerinfor Anal Fissure: Opinion
was Divided on Whether Three Phase III Trials Demonstrateda 'Clinically Meaningful'
Effect, INTERNAL MED. NEWS, June 1, 2006, at 7.
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checklist, 49 FDA "almost universally" applies this standard to its efficacy
Accordingly, what generally constitutes "substantial
evaluations.
evidence" in practice are results that demonstrate drug-effect at a five
percent level of significance.5 1
The measure of statistical significance being at the five percent level is
more or less an artifact of historical chance, when a full range of statistical
52
tables were difficult to publish due to the sheer number of tables required.
As a result, R. A. Fisher's seminal 1925 text on the subject, although
providing tables with multiple levels of significance for other values, only
provided the five percent level for one particular table.53 This value
subsequently became the standard of significance for the biological and
medical sciences. 54
Statistical approaches to data analysis presuppose the existence of
confounding variability within and between sets of data. Statistics is
attempting to solve the difficulty of searching for "scientific truth" in
"randomness." Ultimately however, statistical significance is merely an
arbitrary line along a spectrum of probabilities. When statisticians say that
the statistical significance of a given observation has ap value of 0.05, what
they are saying is that there is a one-in-twenty chance that the observed
difference is a product of random variability within a data set. Said
differently, if there truly was no difference between test articles and the
same experiment were conducted twenty times, we would expect to falsely
"find" a difference once. Statistical analysis, then, is merely a quantified
statement of how confident one is in the conclusions drawn from data.
Statistical significance is placing a bright line along that spectrum in order to
produce a binomial decision-yes there is a difference, or no, there is not.

49. See New Drug and Antibiotic Regulations, 50 Fed. Reg. 7452, 7487 (Feb. 22,
1985) (finalizing 21 C.F.R. § 314.126) ("The agency emphasizes, however, that it applies
the regulation with judgment, not as a check-list").
50.

Katz, supra note 19, at 311.

51.

Gould, supra note 44, at 54.

52. See Stephen Stigler, Fisher and the 5% Level, 21 CHANCE 12, 12 (2008)
(discussing the development of 5% as an adequate measure of significance).
53.

See id.

54. Id.
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Drawing these lines of distinction renders the conclusions of significance
both under-inclusive and over-inclusive. First, observations that clearly
have practical meaning may fall short of statistical significance due to the
statistical power of a given study. For example, if one drug in a given class
demonstrates effectiveness with a p value of 0.04 after a very large clinical
trial, and a second drug within the same class-and as to which all scientific
principles suggest would act similarly-demonstrates effectiveness with a p
value of 0.06 after a smaller study, it would violate reason to say that the
first is effective whereas the second is not. It would also be an inefficient
use of resources (and potentially unethical) to force the sponsor of the
second drug to recruit additional subjects when the result of lowering the p
value to reach 0.05 is more or less a foregone conclusion. Second, data
analysis may show that a statistical significance exists when such a
significance has no meaning in practice. For example, a clinical study for a
topical antibiotic ointment may show that individuals given the treatment, as
opposed to a placebo, had a small, but statistically significant increase in the
development of gastric ulcers. Given that there is no reason to expect that
local, topical application of an antibiotic would have any causal relationship
to ulcers, it should be unnecessary to conduct a full follow-up study to
demonstrate the lack of such a relationship, particularly when other similar
medications are already known not to have such an effect. In each of these
cases, the statistical analysis fails in that it becomes divorced from basic first
principles of science.
IV.

THE WEIGHT OF EVIDENCE ALTERNATIVE

One potential answer to the problems associated with rigid application of
a bright-line statistical rule is a weight of evidence analysis. A weight of
evidence approach to data analysis allows the decision-maker to look at all
data and information, whatever its value, and give each its proper
consideration. For example, this would allow a reviewer to consider a study
whose data demonstrate a statistical p value that, while not technically
meeting a standard definition of "significance," nonetheless provides
evidence of safety or effectiveness. It is important to note that such an
approach does not abandon statistical analysis, but rather borrows from the
Bradford Hill criteria for causation55 when considering the question of
whether the data are indicative of real differences.
Bradford Hill's criteria for causation require an individual to consider nine
specific aspects of a given observation when attempting to determine the
55. See generally Sir Austin Bradford Hill, The Environment and Disease:
Association or Causation?,58 PROC. ROYAL SOc'Y MED. 295, 295-300 (1965).

12
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linkage between the data and the proposed cause.
First, although many
very real and consequential effects are the result of small differences
between a treatment group and a control group, one should give
consideration to the strength of the association between the data and the
hypothesis: the larger the effect, the stronger the association.57 Second, one
must consider the consistency with which a given observation is made. This
consideration is a measure of how robust a given conclusion is with respect
to the experimental question.58 Third, the specificity of the association is
evaluated. This evaluation is a measure of how unique a given association is
relative to other observations. 59 The fourth consideration is the temporal
nature of the observation and the potential cause.60 Fifth, one must evaluate
the dose-response relationship, that is, the relationship between the strength
of the association and the degree of exposure to the alleged causal agent.61
Sixth is that of plausibility, whether the association is congruous with the
scientific possibility of a causal link.62 Seventh, and related to plausibility,
is coherence; causal associations should not be incoherent with generally
known scientific facts.63 Eighth, one may wish to look at an experiment
intended to evaluate the alleged causal relationship.64 This step, however,
brings with it all of the various difficulties already mentioned and must, in
turn, be evaluated based on the other Bradford Hill criteria. Finally, one can
consider whether analogical reasoning supports the proposed causal
association. 65

56.

See generally id.

57.

Id. at 295-96.

58.

See id. at 296.

59.

See id. at 297.

60.

See id.

61.

See Bradford Hill, supra note 55, at 298.

62.

See id.

63.

See id.

64.

See id.

65.

See id. at 299.
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Taken together, when reviewing an individual set of data and the question
of causation, the reviewer should look at the strength of the association (the
statistical analysis) in the context of the data's internal consistency as well as
its coherence with first principles of science and biological plausibility.
Such an approach to data analysis is not new to FDA or to other
government agencies. The Environmental Protection Agency regularly
utilizes a weight of evidence approach to determine acceptable levels of
various substances in drinking water and the atmosphere. 6 6 The FDA also
regularly invokes the weight of evidence concept when communicating
issues of causation, for example, when considering the toxicity of a
regulated product or a qualified health claim for a food. In a 2009 briefing
on the status of FDA regulatory science, the Agency stated that "regulatory
and public health decisions promulgated by the FDA are based upon the
weight of scientific evidence." 67 Nonetheless, FDA rarely articulates what it
means when it says "weight of evidence." In one instance, FDA's Center for
Veterinary Medicine ("CVM") has provided some detail regarding the
Agency's approach to weight of evidence analysis by stating that FDA
"draw[s] on data from a number of sources" including controlled studies on
target populations, non-controlled studies on target populations, and other
studies in the available scientific literature that either involve the specific
product and target population or are related to the product under
consideration.68 Importantly, "[i]rrespective of the source or [level] of

66.

See

U.S.

ENVTL.

PROT. AGENCY,

FACT SHEET: EPA's

GUIDELINES FOR

http://www.epa.gov/cancerguidelines/
(2005),
cancer-guidelines-factsheet.htm ("One of the key components of the hazard assessment is
the analysis of the weight of the evidence."); cf U.S. ENvTL. PROT. AGENCY,
CHROMIUM(Ill), INSOLUBLE SALTS (CASRN 16065-83-1) (1998), http://www.epa.gov/
iris/subst/0028.htm (discussing, in section II, the use of a weight-of-evidence approach to
estimate the carcinogenic risks of oral and inhalation exposure to Chromium (III)
insoluble salts).
CARCINOGEN

RISK

ASSESSMENT

67. FRANK M. TORTI, U.S. FOOD & DRUG ADMIN., REPORT ON STATUS OF
REGULATORY SCIENCE AT FDA: PROGRESS, PLANS AND CHALLENGES (2009),
http://www.fda.gov/ohrms/dockets/ac/09/briefing/chiefscientistrpt.html.
68. See U.S. FOOD & DRUG ADMIN. CTR. FOR VETERINARY MED., BRIEFING PACKET
FOR THE VETERINARY MEDICINE ADVISORY COMMITTEE 2 (2010), http://www.fda.gov/
downloads/AdvisoryCommittees/CommitteesMeetingMaterials/VeterinaryMedicineAdvi
soryCommittee/UCM224762.pdf.
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deference given to a given dataset, all of the data and information is
evaluated in the context of basic scientificprinciples andexternal validity."69

Notably, CVM used a weight of evidence approach to approve a new
animal drug application for ATryn-producing goats in 2009 without the
sponsor submitting a single effectiveness study that would have traditionally
been required under the "substantial evidence" standard.70 In this case,
several factors led FDA to the conclusion that the data nonetheless amounted
to substantial evidence of safety and effectiveness. First, the nature of the
genetic construct used (the drug article) suggested that the article would be
expected to be present only in a localized part of the animal. Second, the
sponsor provided historical records demonstrating overall herd health that
was consistent with traditional herds.7' Finally, because the effect (the
presence of the human biologic in the milk of the goats) is not logically
expected to be present in non-engineered goats, no blinded study was
required; the substantial evidence of effectiveness was established by simpl'
demonstrating that human antithrombin III was present in the goats' milk.
Based on the weight of evidence, as characterized by the data provided in
the context of scientific plausibility, CVM concluded that the data met the
substantial evidence standard statutorily required by the FDCA.7 3 Therefore,
FDA was on solid footing when issuing its approval for the New Animal
Drug Application ("NADA"), and to date, has not been challenged on that
finding. The statutory standards for safety and effectiveness for NADAs are
essentially identical to human new drug applications ("NDAs") 74 (and in
practice, the same for biologic licensing applications ("BLAs") as well).
69.

Id. (emphasis added).

70. See U.S. FOOD & DRUG ADMIN., FREEDOM OF INFORMATION SUMMARY FOR
NADA 141-294 (2009), http://www.fda.gov/downloads/AnimalVeterinary/Products/
ApprovedAnimalDrugProducts/FOIADrugSummaries/UCMl 18087.pdf.

71. This did not include a traditional study, but rather used the broader scientific and
clinical knowledge of general goat herd health, as determined by examination of
published literature as well as the experience of trained veterinarians and animal
scientists. Id.
72.

Id.

73.

Id.

74. Compare FDCA § 505(b)(1), 21 U.S.C. § 355(b)(1) (2006) (NDA requirements)
with FDCA § 512(b)(1), 21 U.S.C. § 360b(b)(1) (2006) (NADA requirements).
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Therefore, it is possible that the same set of circumstances-where scientific
principles lead to the conclusion that the traditional blinded studies do not
add to the regulatory decision-making process-could arise within the
context of a human drug or biologic application, and, if so, a similar
conclusion would be just as scientifically and legally sound.
A.

Weight ofEvidence Evaluations in Practice

While a weight of evidence evaluation generally appeals to logic and the
scientific process, how it is implemented in practice is less clear. A
scientific reviewer at FDA is still tasked with deciding whether there is
substantial evidence that a given product is effective for its proposed
indication.7 5 Turning the "analog" weight of evidence evaluation into a
"digital" regulatory conclusion requires significant expert scientific
judgment. This subjectivity can lead to a lack of clarity or transparency as to
how a regulatory decision-maker arrived at his or her conclusion. It is the
rationale of these decisions that informs future applications and "fills in" the
contours of otherwise ambiguous statutory language.
Therefore, without a general framework to guide the regulatory scientist,
FDA risks the appearance of making arbitrary decisions and sponsors are left
without a full understanding of the expectations for their submissions. A
weight of evidence evaluation, however, need not be a rudderless ship. As is
outlined in the following Table, FDA has provided some broad strokes of
how it conducts such reviews.

75. A weight of evidence review allows FDA staff to determine where along a broad
spectrum of evidence the sum total of support for an application lies. This process,
therefore, can conclude with any one of an infinite number of results between "no data or
Irrespective of how data and
information" and "scientifically irrefutable fact."
information are reviewed by FDA staff, the Agency is ultimately charged with
determining whether or not a given application will be approved. To put it perhaps too
simply, FDA has one of two choices when considering whether to allow a product to be
marketed: "yes" or "no."
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GENERAL CONSIDERATIONS FOR WEIGHT OF EVIDENCE EVALUATIONS

76

BASIC PRINCIPLES OF SCIENCE
(BIOLOGICAL PLAUSIBILITY AND COHERENCE)
EXTERNAL VALIDITY
Order of
Deference
1I

Description
* Controlled Studies
* Same Animal Species
* Internal Validity

Considerations

Example

* Study Quality
* Relevance of Endpoint
to Regulatory Question

*Large, Double Blind
*Use of "Good Study
Practices" such as Good
Clinical Practices
* Full Data Set
*Agreed-to Study
Design

2

* Non-controlled

Studies
* Same Animal Species
* Same Regulated Product

* Study Size / Duration
* Study Quality

*Pilot Study
*Very Small
*Different Endpoint
*Summary Data Only
*No Study Design or
Design Not Followed

3

*

Historical Summary
* Same Animal Species
* Same Regulated Product
*"Epidemiology" Study

* Study and Data Quality

*Not a "Formal Study"
*Lab Records
* Incomplete Records

4

* Studies on Similar or
Related Animal Species
*Different Regulated
Product, but Potentially in
Same or Similar Class

* Degree of Similarity to
the Regulated Product
and the Target Species

* Different Animal
Species
* Different Regulated
Product that is Expected
to Have the Same or
Similar Effect

76. Adapted from U.S. FOOD & DRUG ADMIN. CTR. FOR VETERINARY MED., supra
note 68, at 3.
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When using this approach, an FDA review scientist begins his or her
evaluation of a piece of data or information by considering the various
qualities of the study presented. This "study" may range from the traditional
double-blinded, placebo-controlled study to historical summaries of related
information (even potentially using a different regulated article) in an
entirely different species of animal (for example, a rabbit study using a drug
in the same class as the drug under consideration in the application). The
reviewer considers the various Bradford Hill criteria discussed above,
paying particular attention to the strength and specificity of the association,
as well as the robustness of the study, which would include the evaluation of
study bias. Depending on this evaluation, a reviewer will then be able to
place it along a continuum of deference, from which just four different
points are illustrated in the Table. Importantly, each of the considered data
points is evaluated in the overarching context of biological plausibility and
coherence as well as whether the data are strengthened by external validity,
which is to say whether the data are independently substantiated by other
data or information.
B.

1.

Case Studies

Review ofLong-Adopted Medical Claims

Weight of evidence evaluations could be employed where the medical
community has already accepted the demonstrations of safety and
effectiveness of a specific product claim. In such circumstances, it may be
impractical to conduct clinical trials because of the difficulty in recruiting
physicians to give at least some of the enrolled study subjects the placebo
control.
One example is the prophylactic treatment of the eye with a topical
antibiotic for the purpose of reducing the potential for surgical-related
infection. Well over one million cataract surgeries are performed in the
United States each year.77 Endophthalmitis is a relatively rare infection of
the eye that can, in severe cases, result in significant vision loss even if it is
appropriately treated.78 Numerous clinical studies reported in the scientific

77. Robert E. Fintelmann & Ayman Naseri, Prophylaxis of Postoperative
Endophthalmitis Following CataractSurgery: Current Status and Future Directions, 70
DRUGS 1395, 1397 (2010).
78. See Billy D. Novosad & Michelle C. Callegan, Severe Bacterial
Endophthalmitis: Towards Improving Clinical Outcomes, 5 EXPERT REV.

OPHTHALMOLOGY 689, 689 (2010).
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literature as early as 1952 have shown a marked decrease in the incidence of
post-operative endophthalmitis associated with the prophylactic treatment of
antibiotics after ophthalmic surgery.79 Although there is some recent debate
over whether such treatments are more or less responsible for observed
reductions in incidence rates (as opposed to other factors such as sterile
surgical methods),80 even critics nonetheless recommend prophylactic
antibiotic use in combination with other infection-reducing methods because
the overall risk posed by such use is far outweighed by the risks associated
with endophthalmitis. Clinicians have long stated that "[t]he rationale for
such prophylaxis . .. [is] well founded."82
Nevertheless, no ophthalmic topical antibiotic is currently approved in the
United States for peri- and post-operative use to prevent endophthalmitis.
Due to the potential risks associated with the disease, it is not surprising that
ophthalmologists are not willing to subject their patients to the chance that
they would be given the placebo rather than the antibiotic treatment. This
unwillingness is particularly evident when one considers the number of
patients who would need to enroll in order to demonstrate an effect when the
overall incidence of the disease is so low to begin with. Given that there are
no known risks associated with the use of prophylactic antibiotics (other
than the potential for increased bacterial resistance), and that the vast
majority of U.S. ophthalmologists have successfully used the treatments for
decades (and are likely to continue to use them even in the absence of FDA
approval, thereby negating any decrease in bacterial resistance as a result of
not approving the indication), a weight of evidence approach would allow
FDA to consider all of the known risks and benefits without subjecting
patients to a potential increase in endophthalmitis during a prospective
79. See, e.g., Michael B. Starr, ProphylacticAntibioticsfor Ophthalmic Surgery, 27
SURV. OPHTHALMOLOGY 353, 354 (1983) (Table 1, part B "Series Using One or More

Prophylactic Antibiotics by One or More Routes" versus part A "Series Not Using
Prophylactic Antibiotics").
80. See Christopher N. Ta, Minimizing the Risk of Endophthalmitis Following
Intravitreous Injection, 24 RETINA 699, 702 (2004) (discussing various studies that
support the use of prophylactic antibiotics and others that suggest that it is no more
clinically effective than iodine and sterile surgical procedures).
81. Id. at 702-03 ("Despite the controversy surrounding endophthalmitis prophylaxis,
... [tihe use of topical antibiotics has been shown to reduce conjunctival and eyelid
bacterial flora, which main in turn also decrease the risk of endophthalmitis.").
82.

See, e.g., Starr,supra note 79, at 353.
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clinical study. Should such an analysis have concluded that additional
studies are needed, then sponsors, physicians, and patients would be no
worse off than they are presently. However, if the analysis were to find that
substantial evidence of safety and effectiveness exists when considering the
benefits and risks associated with the intended conditions of use, then the
public is served by having treatments approved for a given therapeutic use
rather than resorting to off-label use by physicians.
2.

Review ofNew Technology

In addition to areas where a body of evidence is readily available to
support an application, a weight of evidence evaluation is also useful in
considering new technologies for which a "one size fits all" approach is not
appealing. In fact, as discussed with regard to CVM's review of genetically
engineered animals, these circumstances are when FDA is more likely
already to have utilized such an approach. As FDA begins to consider how
it will approach the review of biosimilars,83 it has suggested a review
paradigm that sounds very similar to the weight of evidence approach
detailed here. 84
The issue of regulating biosimilars is not as straightforward as one might
think. Unlike their small molecule counterparts, biologics are much more
difficult to characterize fully and manufacture consistently." Furthermore,
slight changes in a biologic's chemical structure, which may or may not be
detectable and which may be impacted by slight variations in the
manufacturin 6 process, can have a dramatic impact on a product's
effectiveness.

83. In 2009, Congress, for the first time, opened FDA's doors to sponsors of generic
versions of approved biologics, generally referred to as "biosimilars." See Biologics
Price Competition and Innovation Act of 2009, Patent Protection and Affordable Care
Act, Pub. L. No. 111-148, §§ 7001-7002, 124 Stat. 804, 804-821.
84.

Id.

85. See Steven Kozlowski et al., Developing the Nation's Biosimilars Program, 365
NEw ENG. J. MED. 385, 385-87 (2011) (noting that "complex structures of biologic
products are usually not easily characterized" and that "the manufacturing processes may
introduce potential variants or impurities that could affect risk").
86.

See id. at 386 (stating that biologics "must have a specific set of structural

features . . . essential to their intended effect, and slight modifications . . . [or] inadvertent

chemical modifications" can affect their performance or safety profile).
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When discussing its intended approach to dealing with these issues, FDA
states that the administration "scientists will need to integrate various types
of information" when making their regulatory decisions. In considering
FDA's historical data analyses, the Agency notes that integrating different
pieces of data and information when considering product applications is a
FDA has proposed using a "totality of the
part of its traditional process.
evidence" approach that evaluates product attributes "with multiple
complementary methods." 89 Recognizing that requiring sponsors to conduct
studies that are unnecessary is unethical, FDA proposes utilizing data and
information that already exists 90 to ensure that any required studies are in
addition to that knowledge and are "carefully tailored to address residual
uncertainty" alone.91
In sum, conducting a weight of evidence evaluation requires scientific
expertise and judgment, but it enables regulatory decision-makers to
consider and give weight to a broader range of data, including information
that might otherwise fail the traditional, yet somewhat arbitrary, definitions
of statistical significance.
V.

OTHER ISSUES TO CONSIDER

Although a weight of evidence approach frees FDA review staff from the
mandatory application of statistical significance evaluation, some legal and
policy issues must be considered before advocating for wide application of
this approach.
First, from a legal perspective, the weight of evidence approach has the
potential to implicate intellectual property concerns. On its face, because no
data is pre-determined to be excluded under a weight of evidence evaluation,
a reviewer should consider all data relevant to the question at hand. This
consideration potentially includes data in the application and available from
other sources-including both public scientific literature as well as data
from other applications that would otherwise be considered proprietary. As
discussed below, this concern could be addressed by explicitly prohibiting

87.

See id

88.

See id.

89.

Id.

90.

See id. at 385.

91.

See Kozlowski et al., supra note 85, at 386.
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the inclusion of confidential data absent appropriate authorization.
However, this alternative is not that different than the current regulatory
paradigm in that the administrative record of decisions cannot be based in
whole or in part on information that is unavailable to the reviewer by virtue
of being proprietary.
Second, although a weight of evidence standard is a different-though not
necessarily a less rigorous-approach to regulatory decision-making when
compared to the evaluation of statistical significance, few individuals fully
understand the limitations of statistical analyses. As a result, most of the
public view statistical significance as representing the "gold standard" of
causal analysis, and therefore any deviation from that approach represents a
lowering of the standards of evaluation. Unfortunately, the complexity of
statistical and weight of evidence analyses renders them difficult to fully
explain in easy-to-digest terms. Correcting errors in public perception about
a change to a weight of evidence standard is likely to be met with broad
statements that rouse fear of risks associated with a true lowering of the
regulatory standard.
Finally, from a policy perspective, a bright-line rule, such as the
traditional approach to the substantial evidence standard, provides little
discretion on the part of the decision maker. Once a reviewer agrees that
required clinical trials have been properly designed and executed, the
statistical analysis of the resulting data is the primary driver of the end
decision. Although, as noted, this approach carries distinct disadvantages, a
weight of evidence approach would incorporate some additional subjectivity,
and potential unpredictability, to the application review process. Therefore,
to the extent that an individual is politically disinclined to give FDA
reviewers additional discretion, there is likely to be resistance to a weight of
evidence approach.
VI.

CONCLUSION

As noted above, FDA already uses weight of evidence approaches in
many contexts, including in aspects of the evaluation of drugs under the
existing statutory standards for safety and effectiveness. However, given the
current statutory limitations on the interpretation of the "substantial
evidence" standard, and the long history of FDA regulatory interpretations
of the standard, a shift to the weight of evidence standard as the general
approach to drug approval would likely require a reframing of the definition
of "substantial evidence" or a rewriting of the standard altogether.
Adopting language by statute or regulation that explicitly allows for
weight of evidence consideration of data has the potential to free FDA from
erroneous criticisms that it would be lowering its standards for safety and
effectiveness. Such language would also be helpful in avoiding any
resistance within the Agency that might incorrectly interpret existing

The Journal of ContemporaryHealth Law and Policy Vol. XXVIll: I

22

statutory provisions and regulations defining substantial evidence as
requiring rote statistical analyses. Finally, such language could be used to
reinforce existing confidentiality rules to ensure that intellectual property, in
the form of data submitted under existing applications, is not used in a
weight of evidence evaluation of other products unless relevant exclusivity
and patent protections have expired.
In conclusion, a weight of evidence approach is one alternative to the
current review paradigm at FDA that allows additional data and information
to be considered during product review. The Agency itself has noted that:
[FDA is] at a critical moment where advances in science are
leading toward fundamental changes in the way medical
treatments and diagnostics are being developed and used . . . .
Regulatory science must be one step ahead to equip FDA with the
necessary tools and methods to reliably assess the safety and
efficacy of products derived from these new scientific
developments, in order to bring the rewards of discovery safely
forward to benefit patients.92
Together, considering any and all available data relevant to a given
product as well as refraining from rote application of statistical analysis,
FDA can further its stated goal of minimizing bias and allowing a scientific
assessment and interpretation of scientific data when evaluating new product
applications. By giving review staff the discretion to review applications
using a weight of evidence approach, they are given-in fact, encouraged to
exercise-the flexibility to consider the application in the broader scientific
context. This flexibility, in turn, will lead to a more scientifically-driven
analysis that will ensure the advancement of FDA regulatory science and the
overall public health.

92.

U.S. FOOD & DRUG ADMIN., supranote 1, at 16-17.

